How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?

Abstract

Maintenance treatment has been used for several years inside clinical trials. Meta-analyses have been published. A new clinical trial (AVAPERL) has been recently published. Despite significant increase of progression-free survival (PFS), overall survival (OS) has not been changed with these strategies. Before a transfer into clinical practices and… (More)
DOI: 10.3978/j.issn.2224-5820.2013.10.01

Topics

Cite this paper

@article{Vergnengre2013HowMD, title={How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?}, author={Alain Vergnen{\'e}gre}, journal={Annals of palliative medicine}, year={2013}, volume={2 4}, pages={170-2} }